Modulatory actions of neuropeptide Y on prostate cancer growth: Role of MAP kinase/ERK 1/2 activatio

Advances in Experimental Medicine and Biology

Volumn 604, Issue , 2007, Pages 96-100

  Ruscica, Massimiliano ^a   Dozio, Elena ^a   Motta, Marcella ^a   Magni, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR;

CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONFERENCE PAPER; HUMAN; HUMAN CELL; MALE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN PHOSPHORYLATION;

EID: 84934434788     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-69116-9_7     Document Type: Conference Paper

References (30)

1. Abrahamsson, P. A. (1999) Neuroendocrine cells in tumor growth of the prostate. Endocr. Relat. Cancer 6, 503-519.
2. Alblas, J., Slager-Davidov, R., Steenbergh, P. H., Sussenbach, J. S. and van der Burg, B. (1998) The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells. Oncogene 16, 131-139.
3. de Herder, W. W., Kwekkeboom, D. J., Valkema, R., Feelders, R. A., van Aken, M. O., Lamberts, S. W., van der Lely, A. J. and Krenning, E. P. (2005) Neuroendocrine tumors and somatostatin: imaging techniques. J. Endocrinol. Invest. 28, 132-136.
4. Gallego, C., Gupta, S. K., Heasley, L. E., Qian, N. X. and Johnson, G. L. (1992) Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat 1a cells. Proc. Natl. Acad. Sci. U. S. A. 89, 7355-7359.
5. Gerald, C., Walker, M. W., Vaysse, P. J., He, C., Branchek, T. A. and Weinshank, R. L. (1995) Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J. Biol. Chem. 270, 26758-26761.
6. Goldberg, Y., Taimor, G., Piper, H. M. and Schluter, K. D. (1998) Intracellular signaling leads to the hypertrophic effect of neuropeptide Y. Am. J. Physiol. 275, C1207-1215.
7. Gordon, E. A., Kohout, T. A. and Fishman, P. H. (1990) Characterization of functional neuropeptide Y receptors in a human neuroblastoma cell line. J. Neurochem. 506-513.
8. Hansel, D. E., Eipper, B. A. and Ronnett, G. V. (2001) Neuropeptide Y functions as a neuroproliferative factor. Nature 410, 940-944.
9. Herzog, H., Hort, Y. J., Ball, H. J., Hayes, G., Shine, J. and Selbie, L. A. (1992) Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. U. S. A. 89, 5794-5798.
10. Keffel, S., Schmidt, M., Bischoff, A. and Michel, M. C. (1999) Neuropeptide-Y stimulation of extracellular signal-regulated kinases in human erythroleukemia cells. J. Pharmacol. Exp. Ther. 291, 1172-1178.
11. Kim, D. S., Park, S. H., Kim, S. E., Kwon, S. B., Park, E. S., Youn, S. W. and Park, K. C. (2003) Lysophosphatidic acid inhibits melanocyte proliferation via cell cycle arrest. Arch. Pharm. Res. 26, 1055-1060.
12. Larhammar, D., Blomqvist, A. G., Yee, F., Jazin, E., Yoo, H. and Wahlestedt, C. (1992) Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J. Biol. Chem. 267, 10935-10938.
13. Mabuchi, S., Ohmichi, M., Kimura, A., Ikebuchi, Y., Hisamoto, K., Arimoto-Ishida, E., Nishio, Y., Takahashi, K., Tasaka, K. and Murata, Y. (2004) Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology 145, 1302-1313.
14. Mack, D., Hacker, G. W., Hauser-Kronberger, C., Frick, J. and Dietze, O. (1997) Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma. E. J. Cancer 33, 317-318.
15. Magni, P. (2003) Hormonal control of the neuropeptide Y system. Curr. Protein Pept. Sci. 4, 45-57.
16. Magni, P. and Motta, M. (2001) Expression of neuropeptide Y receptors in human prostate cancer cells. Ann. Oncol. 12, S27-S29.
17. Michel, M. C., Beck-Sickinger, A., Cox, H., Doods, H. N., Herzog, H., Larhammar, D., Quirion, R., Schwartz, T. and Westfall, T. (1998) XVL International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors. Pharmacol. Rev. 50, 143-150.
18. Mullins, D. E., Zhang, X. and Hawes, B. E. (2002) Activation of extracellular signal regulated protein kinase by neuropeptide Y and pancreatic polypeptide in CHO cells expressing the NPY Y(1), Y(2), Y(4) and Y(5) receptor subtypes. Regul. Pept. 105, 65-73.
19. Nagakawa, O., Ogasawara, M., Murata, J., Fuse, H. and Saiki, I. (2001) Effect of prostatic neuropeptides on migration of prostate cancer cell lines. Int. J. Urol. 8, 65-70.
20. Nagakawa, O., Ogasawara, M., Fujii, H., Murakami, K., Murata, J., fuse, H. and Saiki, I. (1998) Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Lett. 133, 27-33.
21. Nie, M. and Selbie, L. A. (1998) Neuropeptide Y Y1 and Y2 receptor-mediated stimulation of mitogen-activated protein kinase activity. Regul Pept 75-76, 207-213.
22. Pedrazzini, T., Pralong, F. and Grouzmann, E. (2003) Neuropeptide Y: the universal soldier. Cell. Mol. Life Sci. 60, 350-377.
23. Pellieux, C., Sauthier, T., Domenighetti, A., Marsh, D. J., Palmiter, R. D., Brunner, H. R. and Pedrazzini, T. (2000) Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proc. Natl. Acad. Sci. U. S. A. 97, 1595-1600.
24. Pumiglia, K. M. and Decker, S. J. (1997) Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. U. S. A. 94, 448-452.
25. Rasiah, K. K., Kench, J. G., Gardiner-Garden, M., Biankin, A. V., Golovsky, D., Brenner, P. C., Kooner, R., O'Neill G, F., Turner, J. J., Delprado, W., Lee, C. S., Brown, D. A., Breit, S. N., Grygiel, J. J., Horvath, L. G., Stricker, P. D., Sutherland, R. L. and Henshall, S. M. (2006) Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol. Biomark. Prev. 15, 711-716.
26. Reubi, J. C. (1997) Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q. J. Nucl. Med. 41, 63-70.
27. Reubi, J. C., Gugger, M., Waser, B. and Schaer, J. C. (2001) Y1-Mediated Effect of Neuropeptide Y in Cancer: Breast Carcinomas as Targets. Cancer Res. 61, 4636-4641.
28. Ruscica, M., Dozio, E., Boghossian, S., Bovo, G., Martos Riano, V., Motta, M. and Magni, P. (2006) Activation of the Y1 receptor by neuropeptide y regulates the growth of prostate cancer cells. Endocrinology 147, 1466-1473.
29. Tainio, H. (1995) Peptidergic innervation of the human prostate, seminal vesicle and vas deferens. Acta Histochem. 97, 113-119.
30. Ventura, S., Pennefather, J. N. and Mitchelson, F. (2002) Cholinergic innervation and function in the prostate gland. Pharmacol. Ther. 94, 93-112.